Cargando…
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081573/ https://www.ncbi.nlm.nih.gov/pubmed/33932501 http://dx.doi.org/10.1016/j.annonc.2021.04.020 |
| _version_ | 1783685669942460416 |
|---|---|
| author | Palich, R. Veyri, M. Marot, S. Vozy, A. Gligorov, J. Maingon, P. Marcelin, A.-G. Spano, J.-P. |
| author_facet | Palich, R. Veyri, M. Marot, S. Vozy, A. Gligorov, J. Maingon, P. Marcelin, A.-G. Spano, J.-P. |
| author_sort | Palich, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8081573 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80815732021-04-29 Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients Palich, R. Veyri, M. Marot, S. Vozy, A. Gligorov, J. Maingon, P. Marcelin, A.-G. Spano, J.-P. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2021-08 2021-04-29 /pmc/articles/PMC8081573/ /pubmed/33932501 http://dx.doi.org/10.1016/j.annonc.2021.04.020 Text en © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Palich, R. Veyri, M. Marot, S. Vozy, A. Gligorov, J. Maingon, P. Marcelin, A.-G. Spano, J.-P. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients |
| title | Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients |
| title_full | Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients |
| title_fullStr | Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients |
| title_full_unstemmed | Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients |
| title_short | Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients |
| title_sort | weak immunogenicity after a single dose of sars-cov-2 mrna vaccine in treated cancer patients |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081573/ https://www.ncbi.nlm.nih.gov/pubmed/33932501 http://dx.doi.org/10.1016/j.annonc.2021.04.020 |
| work_keys_str_mv | AT palichr weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients AT veyrim weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients AT marots weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients AT vozya weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients AT gligorovj weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients AT maingonp weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients AT marcelinag weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients AT spanojp weakimmunogenicityafterasingledoseofsarscov2mrnavaccineintreatedcancerpatients |